Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | CKS1B | P61024 | 2/20 | 0.49 |
| ▸ | SKP1 | P63208 | 2/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.45 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.45 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22907259 | 0.88 | MAP4K4 (0.53) | MAP4K4CKS1BSKP1SKP2ALDH1A1 | |
| SCHEMBL16333657 | 0.87 | MAP4K4 (0.52) | MAP4K4CKS1BSKP1SKP2ALDH1A1 | |
| SCHEMBL16333807 | 0.87 | MAP4K4 (0.52) | MAP4K4CKS1BSKP1SKP2ALDH1A1 | |
| SCHEMBL27148195 | 0.83 | MAP4K4 (0.55) | MAP4K4CKS1BSKP1SKP2ALDH1A1 | |
| SCHEMBL20046669 | 0.82 | CKS1B (0.58) | MAP4K4CKS1BSKP1SKP2ALDH1A1 | |
| SCHEMBL27099147 | 0.82 | MAP4K4 (0.49) | MAP4K4CKS1BSKP1SKP2ALDH1A1 | |
| SCHEMBL12701240 | 0.81 | KDM4E (0.52) | MAP4K4CKS1BSKP1SKP2ALDH1A1 | |
| SCHEMBL3186820 | 0.80 | CKS1B (0.56) | MAP4K4CKS1BSKP1SKP2ALDH1A1 | |
| SCHEMBL31704852 | 0.79 | GPR119 (0.53) | MAP4K4CKS1BSKP1SKP2ALDH1A1 | |
| SCHEMBL16333318 | 0.79 | MAP4K4 (0.53) | MAP4K4CKS1BSKP1SKP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-114867727-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-3999182-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | MAP4K4 2913/4885CKS1B 352/4885SKP1 2113/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | MAP4K4 2684/4885CKS1B 312/4885SKP1 1711/4885 |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | MAP4K4 2913/4885CKS1B 352/4885SKP1 2113/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | MAP4K4 3321/4885CKS1B 275/4885SKP1 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.